Jun. 30 at 4:59 PM
$BIEL This Chairman’s Update is the strongest strategic communication BIEL has released in years.
It signals real operational progress, validated commercial traction, and a credible pathway toward sustained profitability — all supported by verifiable actions rather than vague forward-looking language.
The update contains four major signals:
BIEL is now profitable (even if small) due to disciplined cost control.
Sales are increasing monthly across both OTC and professional channels.
Electrome partnership has crossed the “execution threshold” — purchase order received, manufacturing underway, commercial launch planning active.
"Manufacturing activities are underway and Electrome is in the planning phase for a commercial launch of BioElectronics' ..."
Strategic positioning is shifting from survival to expansion, with clinical, consumer, professional, and international initiatives all advancing simultaneously.
This is not a “fluff” letter — it’s a milestone update....
(See posted on Ihub by 3331)